Talk:Targeted therapy

Targeted therapy received a peer review by Wikipedia editors, which is now archived. It may contain ideas you can use to improve this article.

A fact from Targeted therapy appeared on Wikipedia's Main Page in the Did you know column on 8 November 2005. The text of the entry was as follows:

Did you know... that targeted therapy is a type of chemotherapy which blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth?

A record of the entry may be seen at Wikipedia:Recent additions/2005/November.

Wikipedia

Medicine: Hematology-oncology Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine
Mid	This article has been rated as Mid-importance on the project's importance scale.
	This article is supported by the Hematology-oncology task force.

Progress and future

The mention of only cannabidiol seems unbalanced. It might be better if we could list targeted therapies in say phase III clinical trials here (if there is no better place) ? Rod57 (talk) 05:57, 28 November 2008 (UTC)[reply]

How about just deleting the example entirely? Adding an example (any example) doesn't really help the reader understand the concept in this case. (I'm not sure that the cannabidiol example is actually accurate. It sounds like it's just low-side-effects systemic therapy.) WhatamIdoing (talk) 02:59, 2 December 2008 (UTC)[reply]

Agreed on all points - it is a systemic therapy, removed. Rdbbbbbb (talk) 19:01, 5 April 2010 (UTC)[reply]

Happy with removal, but not sure a systemic therapy can't also be aimed at a molecular target. Rod57 (talk) 15:53, 14 February 2011 (UTC)[reply]

Should Synta Pharma's ganetespib now be cited in the Small Molecule section? Ganetespib is a unique Triazolone-containing Hsp90 inhibitor, now in phase 2/3 NSCLC trials. If my reading of recent reports is correct, this drug is showing rather considerable promise: (http://clinicaltrials.gov/ct2/show/NCT01348126?intr="STA-9090"&rank=15): efficacy with no ocular or renal toxicity in sizable targeted groups of patients with late stage lung carcinomas that have been unresponsive to other therapies. Ganetespib is a potent inhibitor of Hsp90, structurally unrelated to first-generation ansamycin-family Hsp90 inhibitors, being evaluated in 20 clinical trials, either ongoing, or initiating, with the most advanced being the Phase 2b/3 GLAXAY trial evaluating ganetespib with docetaxel vs docetaxel alone in patients with advanced NSCLC who have progressed on first-line therapy. A global trial evaluating single-agent ganetespib in approximately 100 patients with ALK NSCLC who have not been previously treated with an ALK inhibitor is in the process of initiating. Frankatca (talk) 16:37, 6 March 2012 (UTC)[reply]

Targeted therapies lists so many FDA approved ones that it seems a distraction to try to list individual unapproved/experimental ones. It seems worth mentioning major categories in late stage clinical trials. I'm not sure salinomycin has a molecular target to qualify as a TT even if ever approved. - Rod57 (talk) 20:25, 12 October 2012 (UTC)[reply]

Only for cancer ?

The intro implies they are [only] for cancer. Can 'targeted therapy' not be used for say a targeted treatment for rheumatoid arthritis ? — Preceding unsigned comment added by Rod57 (talk • contribs) 15:35, 14 February 2011

In theory, it's possible for any type of disease. In practice, all of the examples I can think of offhand are—or were originally intended for—treatment of cancer. WhatamIdoing (talk) 19:18, 15 February 2011 (UTC)[reply]

Announce changes

My name is Florian Schaub at Merck KGaA. My aim is to make some changes in this article. From our point of view colorectal cancer and head and neck cancer should be added to the third passage "There are targeted therapies...". In the passage "Monoclonal antibodies" we suggest adding a visual of the cetuximab MOA as an example on the TKI section. In the passage about the agents some changes on cetuximab and panitumumab about EGFR seem useful. Please let me know if anyone has concerns.

--Florian Schaub at Merck KGaA (talk) 10:15, 01 June 2016 (UTC)[reply]

Spam

User:Beetstra,

12.201.243.130 (talk • contribs • deleted contribs • blacklist hits • AbuseLog • what links to user page • COIBot • Spamcheck • count • block log • x-wiki • Edit filter search • WHOIS • RDNS • tracert • robtex.com • StopForumSpam • Google • AboutUs • Project HoneyPot)

keeps adding links to

renointegrativemedicalcenter.com: Linksearch en (insource) - meta - de - fr - simple - wikt:en - wikt:fr • Spamcheck • MER-C X-wiki • gs • Reports: Links on en - COIBot - COIBot-Local • Discussions: tracked - advanced - RSN • COIBot-Link, Local, & XWiki Reports - Wikipedia: en - fr - de • Google: search • meta • Domain: domaintools • AboutUs.com

to this page. It's been reverted three times now. If it comes back, would you prefer that we request a block for the IP, or putting the URL on the spam blacklist? WhatamIdoing (talk) 19:34, 25 February 2020 (UTC)[reply]

WhatamIdoing, I’ll do the latter, it doesn’t look useful elsewhere, and communication is not their best feature. Dirk Beetstra ^{T C} 20:09, 25 February 2020 (UTC)[reply]

Thanks, Dirk. WhatamIdoing (talk) 20:27, 25 February 2020 (UTC)[reply]